Rhythm Pharmaceuticals, Inc. (RYTM)
Nasdaq · Healthcare · Biotechnology
$92.45−0.41%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $6.4B
- 52-week range
- $74.50 – $122.20
- 52-week change
- −5.14%
- EPS (trailing)
- −$3.12
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Revenue
- $190M (+45.82%)
- Net income
- −$197K
- Operating margin
- −101.2%
- Diluted EPS
- −$3.11
- Free cash flow
- −$117M
From the company’s annual report on SEC EDGAR.
About Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc.
Headquarters: Boston, United States · 414 employees · rhythmtx.com